tert-butyl 5-{4-[(2-methyl-4-quinolinyl)methoxy]benzyl}-2,4-dioxohexahydro-5-pyrimidinylcarbamate | 556052-66-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: tert-butyl 5-{4-[(2-methyl-4-quinolinyl)methoxy]benzyl}-2,4-dioxohexahydro-5-pyrimidinylcarbamate
• 英文别名: tert-butyl N-[5-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]methyl]-2,4-dioxo-1,3-diazinan-5-yl]carbamate
• CAS: 556052-66-5
• 化学式: C₂₇H₃₀N₄O₅
• 分子量: 490.559
• InChiKey: PRZDULZKSYTQEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases
  申请人：——

  公开号：US20030166647A1

  公开（公告）日：2003-09-04

  The present application describes novel barbituric acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , W, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-&agr; converting enzyme (TACE) and matrix metalloproteinses (MMP) inhibitors.

  本申请描述了式I的新型巴比妥酸衍生物：1或其药用可接受的盐或前药形式，其中A、B、L、R1、W、Z、Ua、Xa、Ya和Za如本规范中定义，这些衍生物可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• [EN] BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF- DOLLAR G(A) CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES<br/>[FR] DERIVES D'ACIDE BARBITURIQUE UTILISES COMME INHIBITEURS DE L'ENZYME DE CONVERSION DU TNF- DOLLAR G(A) (TACE) ET/OU DE METALLOPROTEINASES MATRICIELLES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003053940A1

  公开（公告）日：2003-07-03

  The present application describes novel barbituric acid derivatives of formula (I), or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, W, Z, U?a, Xa, Ya, and Za¿ are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了新的巴比妥酸衍生物的公式（I），或其药学上可接受的盐或前药形式，其中A、B、L、R1、W、Z、Ua、Xa、Ya和Za在本说明中有定义，它们可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20040058978A1

  公开（公告）日：2004-03-25

  The present invention relates to new substituted indolinones of general formula 1 wherein X and R 1 to R 5 are defined as in claim 1, the isomers and the salts thereof which have valuable properties. The above compounds of general formula I wherein R 1 denotes a hydrogen atom, a C 1-3 -alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein R 1 does not represent a hydrogen atom, a C 1-3 -alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.

  本发明涉及一种新的通式1的取代吲哚酮，其中X和R1至R5的定义如权利要求书1中所述，其异构体和盐具有有价值的性质。通式I中的上述化合物，其中R1表示氢原子，C1-3-烷基或前药基，具有有价值的药理学性质，特别是对多种激酶、病毒细胞周期蛋白和受体酪氨酸激酶具有抑制作用，上述通式I中R1不表示氢原子、C1-3-烷基或前药基的其他化合物是制备上述化合物的有价值中间体。
• US6855710B2
  申请人：——

  公开号：US6855710B2

  公开（公告）日：2005-02-15
• US6936620B2
  申请人：——

  公开号：US6936620B2

  公开（公告）日：2005-08-30